Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine shows promise for rare eye cancer

NCT ID NCT04335890

Disease control Sponsor: Hasumi International Research Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a personalized vaccine made from a patient's own immune cells and tumor material for people with metastatic uveal melanoma, a rare eye cancer that has spread. The vaccine was added to standard treatments like immunotherapy or chemotherapy. The main goals were to check safety and tolerability, with 17 participants enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

17 people

The number who actually took part.

Started

Sep 2020

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed unresectable stage IV metastatic uveal melanoma as per AJCC staging system 2014, 7th edition (updated 2018) not curable with local therapy modalities * WHO performance status of 0, 1 or 2 * age from 18 and ≤ 75 years * negative pregnancy test * signed informed consent Exclusion Criteria: * Major serious illness * evidence for HIV-1, HIV-2, HTLV-1, HBV or HCV infection * active autoimmune disease requiring immunosuppressive therapy * splenectomy or radiation therapy of the spleen * organ allografts * pregnancy * lactation * psychiatric disorders * severe organic brain syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma, uveal metastatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma, uveal metastatic

Contacts and locations

Locations

  • University Hospital Erlangen Dept. of Dermatology

    Erlangen, Bavaria, 91054, Germany